PharmaEssentia Corp (藥華醫藥) shares have jumped 80.56 percent since the company obtained a US polycythemia vera (PV) drug license for its new interferon drug Besremi (ropeginterferon alfa-2b-njft) on Nov. 12.
Shares on Friday closed at NT$195 in Taipei trading, up from the stock’s closing price of NT$108 on Nov. 12.
PV is a rare, chronic and life-threatening blood cancer linked to a stem cell mutation in the bone marrow that results in an overproduction of blood cells and places sufferers at risk of having a blood clot, stroke or heart attack.
Photo: CNA
PharmaEssentia is preparing to make Besremi available in the US in the coming weeks, which is expected to contribute sales and earnings to the company going forward, Yuanta Securities Investment Consulting Co (元大投顧) said in a note on Thursday.
“Besremi is the first first-line PV drug approved by the US Food and Drug Administration (FDA), and can be used on any PV patients regardless of prior treatments,” Yuanta said. “We see a positive outlook for Besremi sales in the US going forward, despite that the new drug’s pricing of US$180,000 per person per year is higher than previously expected.”
In the US, the number of people with PV who are administered Besremi is projected to rise by 800 per year after the drug is launched there, with US sales of Besremi likely to reach US$100 million next year and increase by US$100 million every year after that, Yuanta said.
“Besremi might also cut into the sales of other first and second-line PV drugs, with an estimated revenue of US$900 million in the US in 2030,” it said.
PharmaEssentia last week reported revenue of NT$42.4 million (US$1.52 million) for last month, up 53.2 percent month-on-month and 10.65 percent year-on-year. Cumulative revenue in the first 10 months of the year totaled NT$318.9 million, an increase of 5.13 percent from last year.
With the new drug, the company has high hopes that its balance sheet will improve after posting losses per share of NT$4.74 in the first three quarters of the year, a company regulator filing showed.
In the US, Besremi has been designated an orphan drug for PV, and with the FDA’s approval, PharmaEssentia would have seven years of orphan drug exclusivity (ODE) in the US market.
Aside from the US, Besremi has received approval in Taiwan, the EU and South Korea for PV treatment, the company said.
The company has also recruited 87 people, more than half of the number it plans to recruit, for global clinical phase 3 trials of Besremi to treat essential thrombocythemia, it said.
PharmaEssentia expects to recruit all 160 participants needed for the trials by the second quarter of next year and to complete the trials in the middle of 2023, the company added.
CLIENTS’ RIGHTS: Banking Bureau Deputy Director-General Lin Chih-chi said the buyer and Citibank Taiwan would need to disclose changes to branch operations DBS Bank Taiwan (星展台灣), the local unit of Singapore-based DBS Group Holdings Ltd, has reportedly won a bid to acquire Citibank Taiwan Ltd’s (花旗台灣) consumer banking business, but the two companies declined to confirm the report yesterday. Citibank Taiwan’s consumer banking business is to be sold for about NT$60 billion (US$2.17 billion) to DBS Taiwan, the Chinese-language Economic Daily News reported on Sunday. DBS Taiwan and its parent company are expediting the negotiations with the seller’s US-based parent company, while other local bidders, including Fubon Financial Holding Co (富邦金控) and Cathay Financial Holding Co (國泰金控), have dropped their bids, the report said. Citibank
Intel Corp yesterday said it has placed its first order with ASML Holding NV to purchase the semiconductor industry’s first TWINSCAN EXE: 5200 system, as the US chip giant aims to compete with Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) in advancing to 2-nanometer process technology. The Dutch semiconductor equipment maker’s TWINSCAN EXE:5200 system is an extreme ultraviolet (EUV) high-volume production system with a high numerical aperture (NA) that can produce 220 wafers per hour, more than the 150 wafers that its previous generation TWINSCAN EXE:5000 system can handle. ASML aims to launch the new system in 2024. ASML president and chief
MediaTek Inc (聯發科), the world’s biggest 5G chip supplier, saw its ranking rise by one notch to No. 7 last year among world semiconductor vendors, as it benefited from the rapid 5G smartphone uptake in China after Huawei Technologies Co (華為) was forced to exit the market, Gartner Inc said in a report yesterday. MediaTek’s revenue soared 58.8 percent to US$17.45 billion last year from US$10.99 billion in 2020, outpacing the global semiconductor industry’s growth of 25 percent, according to Gartner’s tally. That gave MediaTek a 3 percent market share. The Hsinchu-based chip company ranked No. 8 in 2020, behind Texas Instruments
South Korea’s antitrust watchdog yesterday fined 23 domestic and foreign shippers a combined 96.2 billion won (US$80.84 million) for price-fixing, including three Taiwanese container shippers — Evergreen Marine Corp (長榮海運), Yang Ming Marine Transport Corp (陽明海運) and Wan Hai Lines Ltd (萬海航運) — the Central News Agency and Japan’s Nikkei Asia reported. Korea Marine Transport Co and Sinokor Merchant Marine Co instigated the collusion by raising freight rates for routes between South Korea and Southeast Asia, China and Japan, and they were later joined by other foreign and domestic firms, the Korea Fair Trade Commission said, citing the results of an
RSS